| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/18/2003 | WO2003075929A1 Inhibitors of histone deacetylase |
| 09/18/2003 | WO2003075924A1 Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
| 09/18/2003 | WO2003075921A2 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 09/18/2003 | WO2003075917A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| 09/18/2003 | WO2003075899A2 Combinations comprising epothilone derivatives and alkylating agents |
| 09/18/2003 | WO2003075891A1 Dispersed solid-containing complex carbohydrate |
| 09/18/2003 | WO2003075876A1 New composition including a pigment assembly comprising a mica core |
| 09/18/2003 | WO2003075857A2 Amino-methyl substituted tetracycline compounds |
| 09/18/2003 | WO2003075850A2 Methods for alzheimer's disease treatment and cognitive enhancement |
| 09/18/2003 | WO2003075847A2 NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS |
| 09/18/2003 | WO2003075844A2 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 09/18/2003 | WO2003075841A2 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/18/2003 | WO2003075840A2 Human antibodies specific to kdr and uses thereof |
| 09/18/2003 | WO2003075839A2 Methods of inducing terminal differentiation |
| 09/18/2003 | WO2003075836A2 Cathepsin cysteine protease inhibitors |
| 09/18/2003 | WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 09/18/2003 | WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 09/18/2003 | WO2003059973A3 Block copolymers |
| 09/18/2003 | WO2003057163A3 Methods for preparing immunoconjugates |
| 09/18/2003 | WO2003057130A3 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 09/18/2003 | WO2003053915A3 Compounds for the treatment of inflammatory disorders |
| 09/18/2003 | WO2003051893A3 Improvements in pharmaceutical compositions |
| 09/18/2003 | WO2003051838A3 Protein kinase inhibitors |
| 09/18/2003 | WO2003051807A3 Improvements in pharmaceutical compositions |
| 09/18/2003 | WO2003046135A3 Osteopontin-related compositions and methods |
| 09/18/2003 | WO2003037897A3 Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases |
| 09/18/2003 | WO2003035105A3 A synthetic chimeric fusion protein with immuno-therapeutic uses |
| 09/18/2003 | WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 09/18/2003 | WO2003033692A3 Use of the adenoviral e2 late promoter |
| 09/18/2003 | WO2003025191A3 Pseudotyped retroviral vector system |
| 09/18/2003 | WO2003024442A3 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 09/18/2003 | WO2003011851A3 Aromatic hydroxamic acid derivatives useful as hdac inhibitors |
| 09/18/2003 | WO2002100901A3 Determination of bone-sialoprotein in bodily fluids for oncological problems |
| 09/18/2003 | WO2002092136A3 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy |
| 09/18/2003 | WO2002085410A3 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls |
| 09/18/2003 | WO2002077267A3 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 09/18/2003 | WO2002072027A3 Oncolytic rna replicons |
| 09/18/2003 | WO2002068455A3 Efficient recovery of correctly refolded proteins |
| 09/18/2003 | WO2002062750A9 Cannabinoid receptor ligands |
| 09/18/2003 | WO2002036625A9 Prokineticin polypeptides, related compositions and methods |
| 09/18/2003 | WO2002036110A9 Oral self-emulsifying formulations of pyranone protease inhibitors |
| 09/18/2003 | WO2002014503A3 Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
| 09/18/2003 | US20030177511 Antitumor, anticancer agents |
| 09/18/2003 | US20030176699 Purine inhibitors of protein kinases, G proteins and polymerases |
| 09/18/2003 | US20030176686 Diagnosis, therapy; animal growth regulators; controlling cell differentiation; antiiinflammatory agents, antihistamines, Crohn's disease, anticancer agents, autoimmune disease |
| 09/18/2003 | US20030176678 Viricides, antitumor agents, antiproliferative agents, anticancer agents; genetic engineered Dna |
| 09/18/2003 | US20030176661 Novel antibody with specificity for colon cancer |
| 09/18/2003 | US20030176650 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 09/18/2003 | US20030176642 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/18/2003 | US20030176620 Synthetic methods for polyphenols |
| 09/18/2003 | US20030176506 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells |
| 09/18/2003 | US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 09/18/2003 | US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof |
| 09/18/2003 | US20030176493 Having antineoplastic activity; antioxidant activity; and inhibit DNA topoisomerase II enzyme |
| 09/18/2003 | US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 09/18/2003 | US20030176487 For therapy and prophylaxis of disorders related to unregulated tyrosine kinase signal transduction, including cell proliferative and metabolic disorders |
| 09/18/2003 | US20030176481 Novel imidazole derivatives with anti-inflammatory activity |
| 09/18/2003 | US20030176465 Cyclic amino acid derivatives |
| 09/18/2003 | US20030176463 For therapy of disease states resulting from angiogenesis; can be administered orally |
| 09/18/2003 | US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin |
| 09/18/2003 | US20030176453 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 09/18/2003 | US20030176451 Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound |
| 09/18/2003 | US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/18/2003 | US20030176438 Useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2) |
| 09/18/2003 | US20030176437 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
| 09/18/2003 | US20030176419 As inhibitors of the retinoic acid-metabolism, as drugs |
| 09/18/2003 | US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors |
| 09/18/2003 | US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 09/18/2003 | US20030176411 Photodynamic therapy for pre-melanomas |
| 09/18/2003 | US20030176405 8 Beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 09/18/2003 | US20030176403 Combination chemotherapy |
| 09/18/2003 | US20030176399 Pharmaceutical formulations comprising indolinone derivatives |
| 09/18/2003 | US20030176393 Product of heat treatment of uronic acid, food, drink or drug including the product |
| 09/18/2003 | US20030176392 Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes ("KHSV") |
| 09/18/2003 | US20030176391 Oral fludara of high-purity formulation with quick release of active ingredient |
| 09/18/2003 | US20030176388 Fatty acid synthase mRNA binding protein |
| 09/18/2003 | US20030176381 Hyaluronic acid in the treatment of cancer |
| 09/18/2003 | US20030176379 Useful in the administration of a drug, therapy |
| 09/18/2003 | US20030176377 DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| 09/18/2003 | US20030176368 For therapy of cancer |
| 09/18/2003 | US20030176359 Administration of a thiol-based chemoprotectant compound |
| 09/18/2003 | US20030176341 For use as an anti-viral, anti-tumour or immunomodulatory agent |
| 09/18/2003 | US20030176336 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/18/2003 | US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer |
| 09/18/2003 | US20030176324 Derivatives of water insoluble drugs which exhibit good activity and water solubility |
| 09/18/2003 | US20030176318 Administering a therapeutically effective amount of a temporary p53 inhibitor to an individual suffering from the disease or condition |
| 09/18/2003 | US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction |
| 09/18/2003 | US20030175969 Prevention infant blood disorders |
| 09/18/2003 | US20030175934 Controlling cell differentiation, cell proliferation; anticancer agents |
| 09/18/2003 | US20030175929 Recombinant human creatine kinase heterodimer with solution-stability |
| 09/18/2003 | US20030175885 Peptides and derivatives thereof showing cell attachment, spreading and detachment activity |
| 09/18/2003 | US20030175884 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 09/18/2003 | US20030175881 Nucleic acids encoding (poly) peptides having chips activity |
| 09/18/2003 | US20030175834 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis |
| 09/18/2003 | US20030175805 Comprises winglesslint 8D (Wnt-8D) polypeptides for treating asthma, nervous system, psychological, alzheimer, cancer, cardiomyopathies, lung and kidney disorders; wound healing agents; tissue engineering |
| 09/18/2003 | US20030175801 Treating cancer via increase in expression of interferons and colony stimulating factors with concomitant decrease in transforming growth factor, prostaglandin and vascular endothelial growth factors expression in cells; immunoassays |
| 09/18/2003 | US20030175775 Ligand for G-protein coupled receptor GPR43 and uses thereof |
| 09/18/2003 | US20030175766 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/18/2003 | US20030175760 Identifying immunotoxin for treatment of cancers; antitumor/antiproliferative/anticarcinogenic agents |
| 09/18/2003 | US20030175753 Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |